| Assay ID | Title | Year | Journal | Article |
|---|
| AID257636 | Inhibitory activity in HUVEC tube formation assay at 100 uM | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
| Angiogenesis inhibitors derived from thalidomide. |
| AID281484 | Inhibition of rabbit liver carboxylesterase expressed in sf21 cells up to 100 uM | 2007 | Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
| Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. |
| AID612391 | Inhibition of human recombinant MAOB expressed in insect cells using kynuramine substrate at 100 uM by fluorescence spectroscopy | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
| Inhibition of monoamine oxidase by C5-substituted phthalimide analogues. |
| AID162144 | Inhibitory activity (RA1) against Prostaglandin G/H synthase 1 was calculated relative to aspirin | 2002 | Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
| Thalidomide and its analogues as cyclooxygenase inhibitors. |
| AID281483 | Inhibition of human liver CE1 expressed in sf21 cells up to 100 uM | 2007 | Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
| Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. |
| AID37431 | Compound was evaluated for binding affinity towards Alpha-glucosidase analyzed by the surface plasma resonance (SPR) method; Not determined | 2000 | Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
| Novel alpha-glucosidase inhibitors with a tetrachlorophthalimide skeleton. |
| AID218272 | In vitro cytotoxicity against human embryonic lung fibroblast WI-38 cells. | 1997 | Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
| Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity. |
| AID257637 | Inhibitory activity in HUVEC tube formation assay at 30 uM | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
| Angiogenesis inhibitors derived from thalidomide. |
| AID1266445 | Induction of bovine LPL stabilization using intralipid as substrate at 25 uM preincubated for 10 mins with human recombinant ANGPTL4 followed by substrate addition measured after 45 mins relative to control | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Structure-activity relationships for lipoprotein lipase agonists that lower plasma triglycerides in vivo. |
| AID1266444 | Induction of bovine LPL stabilization using intralipid as substrate at 12.5 uM preincubated for 10 mins with human recombinant ANGPTL4 followed by substrate addition measured after 45 mins relative to control | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Structure-activity relationships for lipoprotein lipase agonists that lower plasma triglycerides in vivo. |
| AID128449 | Effect on Serum cholesterol levels on CF1 male mice at a dose of 20 (mg/kg)/day after 9 days | 1983 | Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
| Hypolipidemic activity of phthalimide derivatives. 2. N-phenylphthalimide and derivatives. |
| AID439754 | Inhibition of [3H]2-OG binding to human MGL at 1 mM by liquid scintillation counting | 2009 | Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
| Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. |
| AID612390 | Inhibition of human recombinant MAOA expressed in insect cells using kynuramine substrate at 100 uM by fluorescence spectroscopy | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
| Inhibition of monoamine oxidase by C5-substituted phthalimide analogues. |
| AID40425 | Inhibition of Beta-glucosidase activity. | 2000 | Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
| Novel alpha-glucosidase inhibitors with a tetrachlorophthalimide skeleton. |
| AID160735 | Inhibitory activity (RA2) against Prostaglandin G/H synthase 2 was calculated relative to aspirin | 2002 | Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
| Thalidomide and its analogues as cyclooxygenase inhibitors. |
| AID251886 | Cell growth-inhibitory activity toward human leukemia cell line HL60 at 10 uM concentration | 2005 | Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
| Tubulin-polymerization inhibitors derived from thalidomide. |
| AID281482 | Inhibition of human intestinal carboxylesterase expressed in sf21 cells up to 100 uM | 2007 | Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
| Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. |
| AID439746 | Inhibition of [3H]ethanolamine binding to human recombinant FAAH at 1 mM by liquid scintillation counting | 2009 | Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
| Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. |
| AID1266443 | Induction of bovine LPL stabilization using intralipid as substrate at 6.25 uM preincubated for 10 mins with human recombinant ANGPTL4 followed by substrate addition measured after 45 mins relative to control | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Structure-activity relationships for lipoprotein lipase agonists that lower plasma triglycerides in vivo. |
| AID128448 | Effect on Serum cholesterol levels on CF1 male mice at a dose of 20 (mg/kg)/day after 16 days | 1983 | Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
| Hypolipidemic activity of phthalimide derivatives. 2. N-phenylphthalimide and derivatives. |
| AID257638 | Inhibitory activity in HUVEC tube formation assay at 10 uM | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
| Angiogenesis inhibitors derived from thalidomide. |
| AID251887 | Cell growth-inhibitory activity toward human leukemia cell line HL60 at 3 uM concentration | 2005 | Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
| Tubulin-polymerization inhibitors derived from thalidomide. |
| AID1266442 | Induction of bovine LPL stabilization using intralipid as substrate at 3.12 uM preincubated for 10 mins with human recombinant ANGPTL4 followed by substrate addition measured after 45 mins relative to control | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Structure-activity relationships for lipoprotein lipase agonists that lower plasma triglycerides in vivo. |
| AID128463 | Effect on Serum triglyceride levels on CF1 male mice at a dose of 20 (mg/kg)/day after 14 days | 1983 | Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
| Hypolipidemic activity of phthalimide derivatives. 2. N-phenylphthalimide and derivatives. |
| AID81272 | Tumor necrosis factor-alpha production in human leukemia cell line (HL-60) stimulated with 50 nM okadaic acid (OA), at 30 uMolar. | 1997 | Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
| Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity. |
| AID293618 | Cytotoxicity against Vero cells | 2007 | European journal of medicinal chemistry, May, Volume: 42, Issue:5
| Novel and versatile methodology for synthesis of cyclic imides and evaluation of their cytotoxic, DNA binding, apoptotic inducing activities and molecular modeling study. |
| AID37428 | Inhibition of Alpha-glucosidase activity. | 2000 | Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
| Novel alpha-glucosidase inhibitors with a tetrachlorophthalimide skeleton. |
| AID251888 | Cell growth-inhibitory activity toward human leukemia cell line HL60 at 6 uM concentration | 2005 | Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
| Tubulin-polymerization inhibitors derived from thalidomide. |
| AID81275 | Tumor necrosis factor-alpha production in human leukemia cell line (HL-60) stimulated with 10 nM 12-O-tetradecanoylphorbol 13-acetate (TPA) at 30 uMolar. | 1997 | Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
| Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |